Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides. / Gomes, Renata Vitoriano Corradi; Peluso, A. Augusto; Ronchi, Fernanda Aparecida; de Oliveira, Lilian Caroline Gonçalves; Casarini, Dulce Elena; Santos, Robson Augusto Souza; Endlich, Patrick Wander; de Abreu, Glaucia Rodrigues.

In: American Journal of the Medical Sciences, Vol. 367, No. 2, 2024, p. 128-134.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Gomes, RVC, Peluso, AA, Ronchi, FA, de Oliveira, LCG, Casarini, DE, Santos, RAS, Endlich, PW & de Abreu, GR 2024, 'Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides', American Journal of the Medical Sciences, vol. 367, no. 2, pp. 128-134. https://doi.org/10.1016/j.amjms.2023.11.014

APA

Gomes, R. V. C., Peluso, A. A., Ronchi, F. A., de Oliveira, L. C. G., Casarini, D. E., Santos, R. A. S., Endlich, P. W., & de Abreu, G. R. (2024). Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides. American Journal of the Medical Sciences, 367(2), 128-134. https://doi.org/10.1016/j.amjms.2023.11.014

Vancouver

Gomes RVC, Peluso AA, Ronchi FA, de Oliveira LCG, Casarini DE, Santos RAS et al. Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides. American Journal of the Medical Sciences. 2024;367(2):128-134. https://doi.org/10.1016/j.amjms.2023.11.014

Author

Gomes, Renata Vitoriano Corradi ; Peluso, A. Augusto ; Ronchi, Fernanda Aparecida ; de Oliveira, Lilian Caroline Gonçalves ; Casarini, Dulce Elena ; Santos, Robson Augusto Souza ; Endlich, Patrick Wander ; de Abreu, Glaucia Rodrigues. / Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides. In: American Journal of the Medical Sciences. 2024 ; Vol. 367, No. 2. pp. 128-134.

Bibtex

@article{48aecdb0ff84459e957c5baa3f1c6337,
title = "Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides",
abstract = "Cardiovascular diseases (CVD) are the main causes of death in hemodialysis patients, representing a public health challenge. We investigated the effect of different antihypertensive treatments on circulating levels of renin-angiotensin system (RAS) components in end-stage renal disease (ESRD) patients on hemodialysis. ESRD patients were grouped following the prescribed antihypertensive drugs: {\ss}-blocker, {\ss}-blocker+ACEi and {\ss}-blocker+AT1R blocker. ESDR patients under no antihypertensive drug treatment were used as controls. Blood samples were collected before hemodialysis sessions. Enzymatic activities of the angiotensin-converting enzymes ACE and ACE2 were measured through fluorescence assays and plasma concentrations of the peptides Angiotensin II (Ang II) and Angiotensin-(1–7) [Ang-(1–7)] were quantified using mass spectrometry (LC-MS/MS). ACE activity was decreased only in the {\ss}-blocker+ACEi group compared to the {\ss}-blocker+AT1R, while ACE2 activity did not change according to the antihypertensive treatment. Both Ang II and Ang-(1–7) levels also did not change according to the antihypertensive treatment. We concluded that the treatment of ESRD patients on hemodialysis with different antihypertensive drugs do not alter the circulating levels of RAS components.",
keywords = "ACE inhibitor, Angiotensin II, Angiotensin-(1–7), ATR-blocker, Hemodialysis, Hypertension",
author = "Gomes, {Renata Vitoriano Corradi} and Peluso, {A. Augusto} and Ronchi, {Fernanda Aparecida} and {de Oliveira}, {Lilian Caroline Gon{\c c}alves} and Casarini, {Dulce Elena} and Santos, {Robson Augusto Souza} and Endlich, {Patrick Wander} and {de Abreu}, {Glaucia Rodrigues}",
note = "Publisher Copyright: {\textcopyright} 2023",
year = "2024",
doi = "10.1016/j.amjms.2023.11.014",
language = "English",
volume = "367",
pages = "128--134",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides

AU - Gomes, Renata Vitoriano Corradi

AU - Peluso, A. Augusto

AU - Ronchi, Fernanda Aparecida

AU - de Oliveira, Lilian Caroline Gonçalves

AU - Casarini, Dulce Elena

AU - Santos, Robson Augusto Souza

AU - Endlich, Patrick Wander

AU - de Abreu, Glaucia Rodrigues

N1 - Publisher Copyright: © 2023

PY - 2024

Y1 - 2024

N2 - Cardiovascular diseases (CVD) are the main causes of death in hemodialysis patients, representing a public health challenge. We investigated the effect of different antihypertensive treatments on circulating levels of renin-angiotensin system (RAS) components in end-stage renal disease (ESRD) patients on hemodialysis. ESRD patients were grouped following the prescribed antihypertensive drugs: ß-blocker, ß-blocker+ACEi and ß-blocker+AT1R blocker. ESDR patients under no antihypertensive drug treatment were used as controls. Blood samples were collected before hemodialysis sessions. Enzymatic activities of the angiotensin-converting enzymes ACE and ACE2 were measured through fluorescence assays and plasma concentrations of the peptides Angiotensin II (Ang II) and Angiotensin-(1–7) [Ang-(1–7)] were quantified using mass spectrometry (LC-MS/MS). ACE activity was decreased only in the ß-blocker+ACEi group compared to the ß-blocker+AT1R, while ACE2 activity did not change according to the antihypertensive treatment. Both Ang II and Ang-(1–7) levels also did not change according to the antihypertensive treatment. We concluded that the treatment of ESRD patients on hemodialysis with different antihypertensive drugs do not alter the circulating levels of RAS components.

AB - Cardiovascular diseases (CVD) are the main causes of death in hemodialysis patients, representing a public health challenge. We investigated the effect of different antihypertensive treatments on circulating levels of renin-angiotensin system (RAS) components in end-stage renal disease (ESRD) patients on hemodialysis. ESRD patients were grouped following the prescribed antihypertensive drugs: ß-blocker, ß-blocker+ACEi and ß-blocker+AT1R blocker. ESDR patients under no antihypertensive drug treatment were used as controls. Blood samples were collected before hemodialysis sessions. Enzymatic activities of the angiotensin-converting enzymes ACE and ACE2 were measured through fluorescence assays and plasma concentrations of the peptides Angiotensin II (Ang II) and Angiotensin-(1–7) [Ang-(1–7)] were quantified using mass spectrometry (LC-MS/MS). ACE activity was decreased only in the ß-blocker+ACEi group compared to the ß-blocker+AT1R, while ACE2 activity did not change according to the antihypertensive treatment. Both Ang II and Ang-(1–7) levels also did not change according to the antihypertensive treatment. We concluded that the treatment of ESRD patients on hemodialysis with different antihypertensive drugs do not alter the circulating levels of RAS components.

KW - ACE inhibitor

KW - Angiotensin II

KW - Angiotensin-(1–7)

KW - ATR-blocker

KW - Hemodialysis

KW - Hypertension

U2 - 10.1016/j.amjms.2023.11.014

DO - 10.1016/j.amjms.2023.11.014

M3 - Journal article

C2 - 37984736

AN - SCOPUS:85178152168

VL - 367

SP - 128

EP - 134

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 2

ER -

ID: 379081740